Relationship of Brain Natriuretic Peptide (BNP) Levels to Cardiac Diagnosis, Operation Performed, Post-operative Course and Outcome
Recruitment status was Active, not recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to assess brain natriuretic peptide levels to evaluate the relationship of those levels with the diagnosis of congenital cardiac disease, operation performed, post-operative course, and outcome.
| Condition |
|---|
|
Congenital Heart Disease |
| Study Type: | Observational |
| Study Design: | Time Perspective: Retrospective |
| Official Title: | Retrospective Evaluation of Serum B-type Natriuretic Peptide Hormone Levels in Post-operative Patients and the Relationship of BNP Levels to Cardiac Diagnosis, Operation Performed, Post-operative Course and Outcome |
| Estimated Enrollment: | 20 |
| Study Start Date: | April 2005 |
Three types of natriuretic peptides (NP) have been isolated: atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and C-type natriuretic peptide (CNP). The NP family elicits a number of vascular, renal and endocrine effects that help to maintain blood pressure and extracellular fluid volume. These effects are mediated by the specific binding of NP to cell surface receptors that have been characterized, purified and cloned from cells of the vasculature, kidney, adrenal gland and brain. There are 3 subtypes of NP receptors: type A natriuretic peptide receptor (NPRA), type B natriuretic peptide receptor (NPRB), and type C natriuretic peptide receptor (NPRC). All 3 subtypes affect cellular second messenger activity. The literature currently does not define the levels of b-type natriuretic peptide (BNP) in children with congenital heart disease undergoing surgery.
The investigator wishes to perform a retrospective chart review to define BNP levels in the pediatric cardiac defect population and to evaluate the relationship of those levels with cardiac diagnosis, operation performed, post-operative course and outcome. The investigator will collect the following information from the medical record:
- Laboratory: BNP levels, serum pH, lactic acid, Co-ox, CBC, Chemistry
- Diagnosis
- Surgical Procedure
- Incidence of re-operation
- Length of ICU Stay
- Length of Hospital Stay
- Complications
- Length of Ventilation (how many days on the ventilator)
- Medications
- Cross Clamp Time
- Bypass Time
- Echocardiogram data
- Cardiac Catheterization Data
- Vital Signs
- Monitored Hemodynamic Measures
- Final outcome (discharged or death)
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Patients with congenital heart defects
Inclusion Criteria:
- Congenital heart defect
Exclusion Criteria:
- Patients without congenital heart defects
Contacts and Locations| United States, Georgia | |
| Children's Healthcare of Atlanta | |
| Atlanta, Georgia, United States, 30322 | |
| Principal Investigator: | Alecia Wang, MD | Emory University Cardiac Fellow at Children's Healthcare of Atlanta |
More Information
Publications:
| Responsible Party: | Children's Healthcare of Atlanta |
| ClinicalTrials.gov Identifier: | NCT00238810 History of Changes |
| Other Study ID Numbers: | 05.068 |
| Study First Received: | October 12, 2005 |
| Last Updated: | March 14, 2012 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Children's Healthcare of Atlanta:
|
BNP Pediatrics Congenital heart disease b-type natriuretic peptide |
Additional relevant MeSH terms:
|
Heart Diseases Heart Defects, Congenital Cardiovascular Diseases Cardiovascular Abnormalities Congenital Abnormalities Natriuretic Peptide, Brain |
Natriuretic Agents Physiological Effects of Drugs Pharmacologic Actions Cardiovascular Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on May 19, 2013